Emerging modes-of-action in drug discovery.

An increasing focus on complex biology to cure diseases rather than merely treat symptoms has transformed how drug discovery can be approached. Instead of activating or blocking protein function, a growing repertoire of drug modalities can be leveraged or engineered to hijack cellular processes, such as translational regulation or degradation mechanisms. Drug hunters can therefore access a wider arsenal of modes-of-action to modulate biological processes and this review summarises these emerging strategies by highlighting the most representative examples of these approaches.

[1]  Michele Tinti,et al.  ANIA: ANnotation and Integrated Analysis of the 14-3-3 interactome , 2014, Database J. Biol. Databases Curation.

[2]  F. Slack,et al.  MicroRNA therapeutics: towards a new era for the management of cancer and other diseases , 2017, Nature Reviews Drug Discovery.

[3]  Michal Sharon,et al.  Mechanism of auxin perception by the TIR1 ubiquitin ligase , 2007, Nature.

[4]  C. Bennett,et al.  RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. , 2010, Annual review of pharmacology and toxicology.

[5]  David M. Wilson,et al.  Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6. , 2018, ACS chemical biology.

[6]  Chengqi Yi,et al.  Epitranscriptome sequencing technologies: decoding RNA modifications , 2016, Nature Methods.

[7]  K. Chien,et al.  Biocompatible, Purified VEGF-A mRNA Improves Cardiac Function after Intracardiac Injection 1 Week Post-myocardial Infarction in Swine , 2018, Molecular therapy. Methods & clinical development.

[8]  Hiro Furukawa,et al.  Subunit Arrangement and Phenylethanolamine Binding in GluN1/GluN2B NMDA Receptors , 2011, Nature.

[9]  C. Bieberich,et al.  A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. , 2014, Cancer cell.

[10]  Martin C Fillmore,et al.  Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach. , 2018, ACS chemical biology.

[11]  Robert Langer,et al.  Delivery technologies for cancer immunotherapy , 2019, Nature Reviews Drug Discovery.

[12]  M. Disney,et al.  Small Molecule Targeted Recruitment of a Nuclease to RNA. , 2018, Journal of the American Chemical Society.

[13]  A. Citri,et al.  Drug‐induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy , 2002, The EMBO journal.

[14]  M. Brucale,et al.  The chaperone-like protein 14-3-3η interacts with human α-synuclein aggregation intermediates rerouting the amyloidogenic pathway and reducing α-synuclein cellular toxicity. , 2014, Human molecular genetics.

[15]  T. Natsume,et al.  Artificial human Met agonists based on macrocycle scaffolds , 2015, Nature Communications.

[16]  Yuzong Chen,et al.  Phthalimide conjugations for the degradation of oncogenic PI3K. , 2018, European journal of medicinal chemistry.

[17]  Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel–Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7 , 2019 .

[18]  Qidong You,et al.  Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway. , 2018, European journal of medicinal chemistry.

[19]  Stuart L. Schreiber,et al.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes , 1991, Cell.

[20]  U. Rapp,et al.  Regulation of RAF Activity by 14-3-3 Proteins , 2009, Journal of Biological Chemistry.

[21]  Scott A. Peterson,et al.  Inhibiting transthyretin amyloid fibril formation via protein stabilization. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  B. Schwappach,et al.  A dual phosphorylation switch controls 14-3-3-dependent cell surface expression of TASK-1 , 2016, Journal of Cell Science.

[23]  C. Harmon,et al.  Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity , 2018, Nature Communications.

[24]  E. Valeur,et al.  New Modalities, Technologies, and Partnerships in Probe and Lead Generation: Enabling a Mode-of-Action Centric Paradigm. , 2018, Journal of medicinal chemistry.

[25]  A. Ciulli,et al.  SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate , 2019, ACS chemical biology.

[26]  A. Dalgleish,et al.  Lenalidomide: a novel anticancer drug with multiple modalities , 2009 .

[27]  P. Tassone,et al.  MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches , 2018, Journal of Hematology & Oncology.

[28]  H. Lazarus,et al.  The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development , 2011, Therapeutic advances in hematology.

[29]  C. Ottmann,et al.  Small‐molecule stabilization of the p53 – 14‐3‐3 protein‐protein interaction , 2017, FEBS letters.

[30]  Liu Liu,et al.  Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression , 2017, Journal of medicinal chemistry.

[31]  J. Kelly,et al.  Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics , 2003, Science.

[32]  J. Doudna,et al.  Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain , 2017, PLoS biology.

[33]  S. Carr,et al.  Homo-PROTACs for the Chemical Knockdown of Cereblon. , 2018, ACS chemical biology.

[34]  Minoru Ishikawa,et al.  Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins. , 2010, Journal of the American Chemical Society.

[35]  L. M. Stevers,et al.  Characterization and small-molecule stabilization of the multisite tandem binding between 14-3-3 and the R domain of CFTR , 2016, Proceedings of the National Academy of Sciences.

[36]  Ronald A. Li,et al.  Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction , 2013, Nature Biotechnology.

[37]  M. Koegl,et al.  Chemically Induced Degra dation of the Oncogenic Transcription Factor BCL 6 Graphical Abstract Highlights , 2022 .

[38]  L. Jones Small-Molecule Kinase Downregulators. , 2017, Cell chemical biology.

[39]  Yong-Xiang Chen,et al.  Hydrophobic tagging-mediated degradation of Alzheimer's disease related Tau , 2017 .

[40]  C. Crews,et al.  Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. , 2008, Bioorganic & medicinal chemistry letters.

[41]  Jennifer Doudna,et al.  RNA-programmed genome editing in human cells , 2013, eLife.

[42]  I. Churcher Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones? , 2017, Journal of medicinal chemistry.

[43]  Michele Tinti,et al.  14-3-3-Pred: improved methods to predict 14-3-3-binding phosphopeptides , 2015, Bioinform..

[44]  D. Lamont,et al.  Structural basis of PROTAC cooperative recognition for selective protein degradation , 2017, Nature chemical biology.

[45]  Sumit Mittal,et al.  The Molecular Tweezer CLR01 Stabilizes a Disordered Protein–Protein Interface , 2017, Journal of the American Chemical Society.

[46]  C. Dobson,et al.  Protein misfolding, functional amyloid, and human disease. , 2006, Annual review of biochemistry.

[47]  B. Morgan,et al.  Discovery of Small Molecule Ligands for MALAT1 by Tuning an RNA-Binding Scaffold. , 2018, Angewandte Chemie.

[48]  Ali Nahvi,et al.  Discovery of Selective RNA-Binding Small Molecules by Affinity-Selection Mass Spectrometry. , 2018, ACS chemical biology.

[49]  R. Copeland,et al.  RNA-modifying proteins as anticancer drug targets , 2018, Nature Reviews Drug Discovery.

[50]  J. Acker,et al.  Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein complex: involvement of specific residues of the Sec7 domain. , 1999, Molecular cell.

[51]  J. Rossi,et al.  Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[52]  Gary N Parkinson,et al.  The application of DNA and RNA G-quadruplexes to therapeutic medicines. , 2011, Chemical Society reviews.

[53]  C. Crews,et al.  Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy. , 2017, ACS chemical biology.

[54]  P. Loria,et al.  A Small-Molecule Anti-secretagogue of PCSK9 Targets the 80S Ribosome to Inhibit PCSK9 Protein Translation. , 2016, Cell chemical biology.

[55]  C. Crews,et al.  Targeted Protein Internalization and Degradation by ENDosome TArgeting Chimeras (ENDTACs) , 2019, ACS central science.

[56]  Liu Liu,et al.  Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression. , 2018, Journal of medicinal chemistry.

[57]  L. Cantley,et al.  Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation. , 2013, Molecular cell.

[58]  Wei Zhang,et al.  Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors. , 2018, Journal of medicinal chemistry.

[59]  Jeremy L. Jenkins,et al.  Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide , 2014, Nature.

[60]  A. Fournier,et al.  Small-Molecule Stabilization of 14-3-3 Protein-Protein Interactions Stimulates Axon Regeneration , 2017, Neuron.

[61]  Michael L Drummond,et al.  In Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application , 2019, J. Chem. Inf. Model..

[62]  M. Mcdougall,et al.  Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action. , 2018, ACS chemical biology.

[63]  A. Fournier,et al.  14‐3‐3 adaptor protein‐protein interactions as therapeutic targets for CNS diseases , 2017, Pharmacological research.

[64]  James E. Bradner,et al.  Phthalimide conjugation as a strategy for in vivo target protein degradation , 2015, Science.

[65]  Herbert Waldmann,et al.  New Modalities for Challenging Targets in Drug Discovery. , 2017, Angewandte Chemie.

[66]  Jian Min,et al.  New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons. , 2018, ACS medicinal chemistry letters.

[67]  R. M. Sharrard,et al.  Androgen receptor localisation and turnover in human prostate epithelium treated with the antiandrogen, casodex. , 2000, Journal of molecular endocrinology.

[68]  Craig M. Crews,et al.  Induced protein degradation: an emerging drug discovery paradigm , 2016, Nature Reviews Drug Discovery.

[69]  M. Gütschow,et al.  PROTAC-mediated crosstalk between E3 ligases. , 2019, Chemical communications.

[70]  D. Curtis,et al.  Discovery of Small Molecule Splicing Modulators of Survival Motor Neuron-2 (SMN2) for the Treatment of Spinal Muscular Atrophy (SMA). , 2018, Journal of medicinal chemistry.

[71]  C. Crews,et al.  Inducing Protein Degradation as a Therapeutic Strategy. , 2016, Journal of medicinal chemistry.

[72]  A. D. Boer,et al.  Fusicoccanes: diterpenes with surprising biological functions , 2012 .

[73]  Matthew D Disney,et al.  Small Molecule Inhibition of microRNA-210 Reprograms an Oncogenic Hypoxic Circuit. , 2017, Journal of the American Chemical Society.

[74]  M. Koegl,et al.  Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions. , 2019, Journal of medicinal chemistry.

[75]  C. Ottmann,et al.  Stabilization of Protein-Protein Interactions in chemical biology and drug discovery. , 2015, Progress in biophysics and molecular biology.

[76]  R. Place,et al.  Small dsRNAs induce transcriptional activation in human cells , 2006, Proceedings of the National Academy of Sciences.

[77]  James E. Bradner,et al.  Plasticity in binding confers selectivity in ligand induced protein degradation , 2018, Nature Chemical Biology.

[78]  Emilio Alba,et al.  The Functional Interaction of 14-3-3 Proteins with the ERK1/2 Scaffold KSR1 Occurs in an Isoform-specific Manner* , 2008, Journal of Biological Chemistry.

[79]  C. Ottmann,et al.  A semisynthetic fusicoccane stabilizes a protein-protein interaction and enhances the expression of K+ channels at the cell surface. , 2013, Chemistry & biology.

[80]  Christopher J. Ott,et al.  Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands , 2018, Nature Chemical Biology.

[81]  Luke A. Gilbert,et al.  CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes , 2013, Cell.

[82]  C. Ottmann,et al.  Molecular tweezers modulate 14-3-3 protein-protein interactions. , 2013, Nature chemistry.

[83]  M. Disney,et al.  Recent advances in developing small molecules targeting RNA. , 2012, ACS chemical biology.

[84]  C. Dominguez,et al.  Identification of G-quadruplexes in long functional RNAs using 7-deaza-Guanine RNA , 2016, Nature chemical biology.

[85]  Eric T. Wang,et al.  Precise small-molecule cleavage of an r(CUG) repeat expansion in a myotonic dystrophy mouse model , 2019, Proceedings of the National Academy of Sciences.

[86]  W. Zwart,et al.  Interaction of 14-3-3 proteins with the Estrogen Receptor Alpha F domain provides a drug target interface , 2013, Proceedings of the National Academy of Sciences.

[87]  Jing Wang,et al.  The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study. , 2017, Cell chemical biology.

[88]  S. Solomon,et al.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[89]  C. Ottmann,et al.  Rationally Designed Semisynthetic Natural Product Analogues for Stabilization of 14-3-3 Protein-Protein Interactions. , 2018, Angewandte Chemie.

[90]  J. Ovádi,et al.  Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals). , 2017, Journal of medicinal chemistry.

[91]  I. E. Smith,et al.  PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding. , 2019, ACS chemical biology.

[92]  T. Corson,et al.  Small-Molecule Hydrophobic Tagging Induced Degradation of HaloTag Fusion Proteins , 2011, Nature Chemical Biology.

[93]  L. M. Stevers,et al.  Modulators of 14-3-3 Protein–Protein Interactions , 2017, Journal of medicinal chemistry.

[94]  Sanjiv J. Shah,et al.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.

[95]  J. Rizo,et al.  Jasmonate perception by inositol phosphate-potentiated COI1-JAZ co-receptor , 2010, Nature.

[96]  Robert Langer,et al.  Inhaled Nanoformulated mRNA Polyplexes for Protein Production in Lung Epithelium , 2019, Advanced materials.

[97]  M. Ueffing,et al.  Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3 , 2013, Proceedings of the National Academy of Sciences.

[98]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[99]  N. Gray,et al.  Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML. , 2019, Cell chemical biology.

[100]  A. Ciulli,et al.  Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4 , 2015, ACS chemical biology.

[101]  P. Workman,et al.  Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766) , 2017, Journal of medicinal chemistry.

[102]  Shaomeng Wang,et al.  Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER). , 2019, Journal of medicinal chemistry.

[103]  K. Chien,et al.  Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes , 2019, Nature Communications.

[104]  A. Prasad,et al.  Nucleic acid therapeutics: basic concepts and recent developments , 2014 .

[105]  D. Alessi,et al.  Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation , 2017, Nature Communications.

[106]  L. Hedstrom,et al.  Boc3Arg-Linked Ligands Induce Degradation by Localizing Target Proteins to the 20S Proteasome. , 2016, ACS chemical biology.

[107]  R. Young,et al.  Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. , 2017, Nature chemical biology.

[108]  Yanchang Wang,et al.  14-3-3 protein targets misfolded chaperone-associated proteins to aggresomes , 2013, Journal of Cell Science.

[109]  James C Sacchettini,et al.  Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. , 2004, Journal of medicinal chemistry.

[110]  Vincent L. Butty,et al.  Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription. , 2019, Cell chemical biology.

[111]  Michael Reutlinger,et al.  Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA). , 2018, Journal of medicinal chemistry.

[112]  T. Tsuruo,et al.  Small Molecules Destabilize cIAP1 by Activating Auto-ubiquitylation* , 2008, Journal of Biological Chemistry.

[113]  S. Carr,et al.  Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells , 2014, Science.

[114]  Y. T. Wang,et al.  Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation , 2014, Nature Neuroscience.

[115]  G. Petzold,et al.  Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase , 2016, Nature.

[116]  Yong-Xiang Chen,et al.  TDP-43 specific reduction induced by Di-hydrophobic tags conjugated peptides. , 2019, Bioorganic chemistry.

[117]  Charles H Jones,et al.  Overcoming Gene-Delivery Hurdles: Physiological Considerations for Nonviral Vectors. , 2016, Trends in biotechnology.

[118]  S. Fisher,et al.  Targeted protein degradation and the enzymology of degraders. , 2018, Current opinion in chemical biology.

[119]  M. Skwarczynska,et al.  Stabilization of physical RAF/14-3-3 interaction by cotylenin A as treatment strategy for RAS mutant cancers. , 2013, ACS chemical biology.

[120]  Y. Xiong,et al.  Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). , 2018, European journal of medicinal chemistry.

[121]  Jeffrey Skolnick,et al.  The distribution of ligand-binding pockets around protein-protein interfaces suggests a general mechanism for pocket formation , 2012, Proceedings of the National Academy of Sciences.

[122]  Alexander Meissner,et al.  Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. , 2010, Cell stem cell.

[123]  Stuart L. Schreiber,et al.  A mammalian protein targeted by G1-arresting rapamycin–receptor complex , 1994, Nature.

[124]  L. Pusztai,et al.  The cell cycle regulator 14-3-3σ opposes and reverses cancer metabolic reprogramming , 2015, Nature Communications.

[125]  W. Gilbert,et al.  Messenger RNA modifications: Form, distribution, and function , 2016, Science.

[126]  Kathleen A. Boyle,et al.  Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction , 2019, Nature Communications.

[127]  Gaurav Sahay,et al.  Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[128]  Jonas Korlach,et al.  The birth of the Epitranscriptome: deciphering the function of RNA modifications , 2012, Genome Biology.

[129]  N. Rizvi,et al.  RNA as a small molecule druggable target. , 2017, Bioorganic & medicinal chemistry letters.

[130]  Anirvan Ghosh,et al.  SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy , 2014, Science.

[131]  Michael Hann,et al.  Stabilization of protein-protein interactions in drug discovery , 2017, Expert opinion on drug discovery.

[132]  Lukasz Skóra,et al.  Site-Directed Fragment-Based Screening for the Discovery of Protein-Protein Interaction Stabilizers. , 2019, Journal of the American Chemical Society.

[133]  M. Disney,et al.  Precise Small Molecule Degradation of a Noncoding RNA Identifies Cellular Binding Sites and Modulates an Oncogenic Phenotype. , 2018, ACS chemical biology.

[134]  Shaomeng Wang,et al.  Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. , 2019, Journal of medicinal chemistry.

[135]  M. Schapira Structural Chemistry of Human RNA Methyltransferases. , 2016, ACS chemical biology.

[136]  Salvador Ventura,et al.  Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity , 2016, Nature Communications.

[137]  D. Spector,et al.  Selective Small-Molecule Targeting of a Triple Helix Encoded by the Long Noncoding RNA, MALAT1. , 2019, ACS chemical biology.

[138]  K. Weeks,et al.  Principles for targeting RNA with drug-like small molecules , 2018, Nature Reviews Drug Discovery.

[139]  Lukasz Skóra,et al.  Identification of Two Secondary Ligand Binding Sites in 14-3-3 Proteins Using Fragment Screening , 2017, Biochemistry.

[140]  A. Ciulli,et al.  3-Fluoro-4-hydroxyprolines: Synthesis, Conformational Analysis, and Stereoselective Recognition by the VHL E3 Ubiquitin Ligase for Targeted Protein Degradation , 2018, Journal of the American Chemical Society.

[141]  A. Gregory Matera,et al.  A day in the life of the spliceosome , 2014, Nature Reviews Molecular Cell Biology.

[142]  H. Zoghbi,et al.  Regional rescue of spinocerebellar ataxia type 1 phenotypes by 14-3-3ε haploinsufficiency in mice underscores complex pathogenicity in neurodegeneration , 2011, Proceedings of the National Academy of Sciences.

[143]  Özlem Türeci,et al.  mRNA-based therapeutics — developing a new class of drugs , 2014, Nature Reviews Drug Discovery.

[144]  T. Veenstra,et al.  Protein Phosphatase 2A Positively Regulates Ras Signaling by Dephosphorylating KSR1 and Raf-1 on Critical 14-3-3 Binding Sites , 2003, Current Biology.

[145]  Thomas M. Smith,et al.  SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. , 2015, Nature chemical biology.

[146]  Covalent small-molecule-RNA complex formation enables cellular profiling of small-molecule-RNA interactions. , 2013, Angewandte Chemie.

[147]  C. Crews,et al.  Chemical biology: Greasy tags for protein removal , 2012, Nature.

[148]  J. Doudna,et al.  The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.

[149]  Chad J. Miller,et al.  A comprehensive mathematical model for three-body binding equilibria. , 2013, Journal of the American Chemical Society.

[150]  C. Ottmann,et al.  Structural characterization of 14-3-3ζ in complex with the human Son of sevenless homolog 1 (SOS1). , 2018, Journal of structural biology.

[151]  R. Labaudinière,et al.  Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade , 2012, Proceedings of the National Academy of Sciences.

[152]  J. Doudna,et al.  Cornerstones of CRISPR–Cas in drug discovery and therapy , 2016, Nature Reviews Drug Discovery.

[153]  N. Leclerc,et al.  Interaction of 14-3-3ζ with microtubule-associated protein tau within Alzheimer's disease neurofibrillary tangles. , 2013, Biochemistry.

[154]  N. Dumaz,et al.  Protein Kinase A Blocks Raf-1 Activity by Stimulating 14-3-3 Binding and Blocking Raf-1 Interaction with Ras* , 2003, Journal of Biological Chemistry.

[155]  Christopher J. Ott,et al.  The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.

[156]  C. Loh,et al.  Targeted protein degradation mechanisms. , 2019, Drug discovery today. Technologies.

[157]  L. Camoni,et al.  The phytotoxin fusicoccin, a selective stabilizer of 14‐3‐3 interactions? , 2013, IUBMB life.

[158]  Irene Lostalé‐Seijo,et al.  Synthetic materials at the forefront of gene delivery , 2018, Nature Reviews Chemistry.

[159]  Hiroki Kato,et al.  Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[160]  Kenneth P Nephew,et al.  Fulvestrant (ICI 182,780)-dependent Interacting Proteins Mediate Immobilization and Degradation of Estrogen Receptor-α* , 2006, Journal of Biological Chemistry.

[161]  P. Jänne,et al.  Pharmacological Targeting of the Pseudokinase Her3 , 2014, Nature chemical biology.

[162]  C. Crews,et al.  Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase , 2019, Nature Communications.

[163]  Liu Liu,et al.  Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. , 2018, Journal of Medicinal Chemistry.

[164]  Weiping Tang,et al.  Development of the first small molecule histone deacetylase 6 (HDAC6) degraders. , 2018, Bioorganic & medicinal chemistry letters.

[165]  A. Rabow,et al.  Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist. , 2015, Journal of medicinal chemistry.

[166]  C. Crews,et al.  Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead. , 2017, Cell chemical biology.

[167]  W. L. Jorgensen,et al.  Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α. , 2012, Angewandte Chemie.

[168]  R. J. Ramamurthi,et al.  Nusinersen versus Sham Control in Infantile‐Onset Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[169]  Philippe P Roux,et al.  RSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively regulating MAPK activation. , 2012, The Biochemical journal.

[170]  K. Read,et al.  Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase: Structure–Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrroli , 2017, Journal of medicinal chemistry.

[171]  Dennis L. Buckley,et al.  Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging. , 2015, Angewandte Chemie.

[172]  Markus Kaiser,et al.  Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery? , 2012, Angewandte Chemie.

[173]  Francine E. Garrett-Bakelman,et al.  The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal and leukemia cells , 2017, Nature Medicine.

[174]  S R Sprang,et al.  Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsalpha.GTPgammaS. , 1997 .

[175]  C. Ottmann,et al.  Small‐Molecule Stabilization of the 14‐3‐3/Gab2 Protein–Protein Interaction (PPI) Interface , 2016, ChemMedChem.

[176]  A. Ciulli,et al.  Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders , 2017, Essays in biochemistry.

[177]  R. Falk,et al.  Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. , 2005, Archives of internal medicine.

[178]  J. Berger,et al.  Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[179]  A. Plowright,et al.  Joining Forces: The Chemical Biology-Medicinal Chemistry Continuum. , 2017, Cell chemical biology.

[180]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.